Wait, we have a special offer for you! ✋

Get your exclusive discount now

Use FY25SAVE to get flat 20% off on the report No, I'd pay the full price

Terms & Conditions : This coupon is vaild exclusively for Global Market Reports 2025 and can be used Until March 31 , 2025 .

Global Vaxneuvance Market Report 2025

Vaxneuvance Market Report 2025: Epidemiology, Pipeline Analysis, Market Size, Trends, And Global Forecast 2034 – By Indication (Pneumonia, Meningitis, Sepsis, Bacteremia, Otitis Media), By Distribution Channel (Pharmacies, Hospitals), By End User (Adults, Children, Geriatric Population)

Vaxneuvance Global Market Report 2025

Report Price : $4490.00 | Pages : | Published : January 2025 | Delivery Time: 2-3 business days | Format : pdf

Purchase Options
Request a Sample
Request For Discount
Customise Your Report
Item added to cart!
Request For Proposal
Request For Regional Data
FAQs

Need assistance or more information before the purchase?

Enquire Before Buying
Vaxneuvance Global Market Report 2025

Proud Members Of

checkslacipN checkaoirsN checkscipN
Description Table Of Contents Tables & Figures Market Insights Related Reports

Vaxneuvance Market Definition

Vaxneuvance is a pneumococcal conjugate vaccine designed to protect against invasive diseases caused by specific strains of Streptococcus pneumoniae in adults and children. The vaccine works by stimulating the immune system to recognize and fight 15 serotypes of the bacteria, providing broad protection.

The main indication for vaxneuvance is pneumonia, meningitis, sepsis, bacteremia, and otitis media. Pneumonia is an infection that inflames the air sacs in the lungs, causing symptoms such as cough, fever, and difficulty breathing. Vaxneuvance helps prevent pneumococcal pneumonia by targeting specific serotypes of the streptococcus pneumoniae bacteria. The various distribution channels include pharmacies and hospitals, and several end users including adults, children, and geriatric population.

Vaxneuvance Market Segmentation

The vaxneuvance market covered in this report is segmented –

1) By Indication: Pneumonia; Meningitis; Sepsis; Bacteremia; Otitis Media

2) By Distribution Channel: Pharmacies; Hospitals

3) By End User: Adults; Children; Geriatric Population

Vaxneuvance Market Size and growth rate 2025 to 2029: Graph

Vaxneuvance Market Size 2025 And Growth Rate

The vaxneuvance market size has XX (HCAGR) in recent years. It will grow from $XX million in 2024 to $XX million in 2025 at a compound annual growth rate (CAGR) of XX%. The growth in the historic period can be attributed to rise in incidence of pneumococcal diseases, rise in aging population, rise in supportive regulatory approvals, rise in government funding for vaccination, and increase in travel and globalization.

Vaxneuvance Market Growth Forecast

The vaxneuvance market size is expected to see XX (FCAGR) in the next few years. It will grow to $XX million in 2029 at a compound annual growth rate (CAGR) of XX%. The growth in the forecast period can be attributed to rising chronic conditions, rising antimicrobial resistance, rising respiratory infections in children, increasing cases of immunocompromised populations, and rising healthcare investments. Major trends in the forecast period include development of needle-free vaccine delivery systems, advancements in cold-chain technologies, integration of AI-powered supply chain optimization, integration with digital health records for tracking immunizations, and innovations in adjuvant systems to boost immune response.

Book your 30 minutes free consultation with our research experts

Contact Us

Vaxneuvance Market Driver: Impact Of High Pneumonia Prevalence On Vaccine Demand

The prevalence of pneumonia is expected to drive the growth of the vaxneuvance market going forward. Pneumonia is an infection that causes inflammation in the air sacs of one or both lungs, filling with fluid or pus, resulting in symptoms such as coughing, fever, and breathing difficulties. The prevalence of pneumonia is driven by factors such as viral and bacterial infections, weakened immune systems, air pollution, and the increasing aging population, which makes individuals more susceptible to respiratory infections. Vaxneuvance helps patients by protecting against pneumonia caused by 15 strains of Streptococcus pneumoniae, reducing the risk of severe infections and related complications. For instance, in 2024, according to the Johns Hopkins University, a US-based research university, the mean Pneumonia GAPPD (Global Action Plan for Pneumonia and Diarrhea) score across 15 countries was 56%, an increase of 2% from 54% in 2023. Therefore, the high prevalence of pneumonia is driving the growth of the vaxneuvance market.

Vaxneuvance Market Driver: Role Of Increasing R&D Investments In Advancing Vaccine Innovation

The growth in research and development investments is expected to drive the vaxneuvance market going forward. Investments in research and development are growing due to increasing demand for innovation and the need to address complex global challenges such as healthcare, sustainability, and digital transformation. The growing investments in research and development support Vaxneuvance by enhancing its vaccine technology and expanding its potential to address evolving healthcare needs. For instance, in July 2024, according to the Department of Health and Social Care, a UK-based government department responsible for the nation's health and social care, in 2022, pharmaceutical research and development in the UK totaled $11.4 billion (£9.0 billion), representing 0.36% of GDP and 18% of all business R&D, the highest among product areas. Therefore, the growth in investments in research and development is driving the growth of the vaxneuvance market.

Global Vaxneuvance Market Major Players

Major companies operating in the vaxneuvance market are Merck & Co. Inc.

Global Vaxneuvance Market Trend: Expanding Indications To Enhance Vaccine Accessibility And Impact

The key trend in the vaxneuvance market is vaccine-expanded indications to broaden its target patient population. Expanded indications address unmet medical needs and enhance the vaccine's utility in preventing pneumococcal diseases across diverse age groups. For instance, in June 2022, Merck & Co. Inc., a US-based pharmaceutical company, announced that the United States Food and Drug Administration (FDA) expanded vaxneuvance approval to include children aged 6 weeks to 17 years for preventing invasive pneumococcal disease caused by 15 serotypes. This approval underscores its clinical significance but advises against use in individuals with severe allergies to its ingredients.

Regional Analysis For The Global Vaxneuvance Market

North America was the largest region in the vaxneuvance market in 2024. The regions covered in the vaxneuvance market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the vaxneuvance market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Vaxneuvance Market?

The vaxneuvance market consists of sales of pneumococcal 15-valent conjugate vaccines, adjuvants, vaccine administration supplies, and cold chain equipment. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What is the Market Assessment and Strategic Outlook for the Vaxneuvance Industry?

The vaxneuvance market research report is one of a series of new reports from The Business Research Company that provides vaxneuvance market statistics, including the vaxneuvance industry's global market size, regional shares, competitors with a vaxneuvance market share, detailed vaxneuvance market segments, market trends and opportunities, and any further data you may need to thrive in the vaxneuvance industry. This vaxneuvance market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Vaxneuvance Market Report Forecast Analysis
Report AttributeDetails
Market Size Value In 2025 Included ?
Revenue Forecast In 2034 Included ?
Growth Rate Included ?
Base Year For Estimation 2024
Actual Estimates/Historical Data 2019-2024
Forecast Period 2025 - 2029 - 2034
Market Representation Revenue in USD Billion and CAGR from 2025 to 2034
Segments Covered The vaxneuvance market covered in this report is segmented –
1) By Indication: Pneumonia; Meningitis; Sepsis; Bacteremia; Otitis Media
2) By Distribution Channel: Pharmacies; Hospitals
3) By End User: Adults; Children; Geriatric Population
Regional Scope Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Country Scope The countries covered in the report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain. Additional countries that can be covered in the report are Bangladesh, Thailand, Vietnam, Malaysia, Singapore, Philippines, Hong Kong, New Zealand, Mexico, Chile, Argentina, Colombia, Peru, Austria, Belgium, Denmark, Finland, Ireland, Netherlands, Norway, Portugal, Sweden, Switzerland, Czech Republic, Poland, Romania, Ukraine, Saudi Arabia, Israel, Iran, Turkey, UAE, Egypt, Nigeria, South Africa.
Key Companies Profiled Merck & Co. Inc.
Customization ScopeRequest for Sample
Pricing And Purchase OptionsExplore Purchase Options

    Table Of Contents

    1. Executive Summary

    2. Vaxneuvance Market Characteristics

    3. Vaxneuvance Market Biologic Drug Characteristics

    3.1. Molecule Type

    3.2. Route Of Administration (ROA)

    3.3. Mechanism Of Action (MOA)

    3.4. Safety And Efficacy

    4. Vaxneuvance Market Trends And Strategies

    5. Vaxneuvance Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

    6. Global Vaxneuvance Growth Analysis And Strategic Analysis Framework

    6.1. Global Vaxneuvance PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)

    6.2. Analysis Of End Use Industries

    6.3. Global Vaxneuvance Market Growth Rate Analysis

    6.4. Global Vaxneuvance Historic Market Size and Growth, 2019 - 2024, Value ($ Million)

    6.5. Global Vaxneuvance Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Million)

    6.6. Global Vaxneuvance Total Addressable Market (TAM)

    7. Global Vaxneuvance Pricing Analysis & Forecasts

    8. Vaxneuvance Market Segmentation

    8.1. Global Vaxneuvance Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

    Pneumonia

    Meningitis

    Sepsis

    Bacteremia

    Otitis Media

    8.2. Global Vaxneuvance Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

    Pharmacies

    Hospitals

    8.3. Global Vaxneuvance Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

    Adults

    Children

    Geriatric Population

    9. Global Vaxneuvance Epidemiology Of Clinical Indications

    9.1. Drug Side Effects

    9.2. Incidence And Prevalence of Clinical Indications

    10. Vaxneuvance Market Regional And Country Analysis

    10.1. Global Vaxneuvance Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

    10.2. Global Vaxneuvance Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

    11. Asia-Pacific Vaxneuvance Market

    11.1. Asia-Pacific Vaxneuvance Market Overview

    Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

    11.2. Asia-Pacific Vaxneuvance Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

    11.3. Asia-Pacific Vaxneuvance Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

    11.4. Asia-Pacific Vaxneuvance Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

    12. China Vaxneuvance Market

    12.1. China Vaxneuvance Market Overview

    12.2. China Vaxneuvance Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Million

    12.3. China Vaxneuvance Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Million

    12.4. China Vaxneuvance Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Million

    13. India Vaxneuvance Market

    13.1. India Vaxneuvance Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

    13.2. India Vaxneuvance Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

    13.3. India Vaxneuvance Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

    14. Japan Vaxneuvance Market

    14.1. Japan Vaxneuvance Market Overview

    14.2. Japan Vaxneuvance Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

    14.3. Japan Vaxneuvance Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

    14.4. Japan Vaxneuvance Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

    15. Australia Vaxneuvance Market

    15.1. Australia Vaxneuvance Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

    15.2. Australia Vaxneuvance Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

    15.3. Australia Vaxneuvance Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

    16. South Korea Vaxneuvance Market

    16.1. South Korea Vaxneuvance Market Overview

    16.2. South Korea Vaxneuvance Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

    16.3. South Korea Vaxneuvance Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

    16.4. South Korea Vaxneuvance Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

    17. Western Europe Vaxneuvance Market

    17.1. Western Europe Vaxneuvance Market Overview

    17.2. Western Europe Vaxneuvance Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

    17.3. Western Europe Vaxneuvance Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

    17.4. Western Europe Vaxneuvance Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

    18. UK Vaxneuvance Market

    18.1. UK Vaxneuvance Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

    18.2. UK Vaxneuvance Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

    18.3. UK Vaxneuvance Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

    19. Germany Vaxneuvance Market

    19.1. Germany Vaxneuvance Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

    19.2. Germany Vaxneuvance Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

    19.3. Germany Vaxneuvance Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

    20. France Vaxneuvance Market

    20.1. France Vaxneuvance Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

    20.2. France Vaxneuvance Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

    20.3. France Vaxneuvance Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

    21. Eastern Europe Vaxneuvance Market

    21.1. Eastern Europe Vaxneuvance Market Overview

    21.2. Eastern Europe Vaxneuvance Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

    21.3. Eastern Europe Vaxneuvance Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

    21.4. Eastern Europe Vaxneuvance Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

    22. North America Vaxneuvance Market

    22.1. North America Vaxneuvance Market Overview

    22.2. North America Vaxneuvance Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

    22.3. North America Vaxneuvance Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

    22.4. North America Vaxneuvance Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

    23. USA Vaxneuvance Market

    23.1. USA Vaxneuvance Market Overview

    23.2. USA Vaxneuvance Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

    23.3. USA Vaxneuvance Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

    23.4. USA Vaxneuvance Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

    24. Canada Vaxneuvance Market

    24.1. Canada Vaxneuvance Market Overview

    24.2. Canada Vaxneuvance Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

    24.3. Canada Vaxneuvance Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

    24.4. Canada Vaxneuvance Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

    25. South America Vaxneuvance Market

    25.1. South America Vaxneuvance Market Overview

    25.2. South America Vaxneuvance Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

    25.3. South America Vaxneuvance Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

    25.4. South America Vaxneuvance Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

    26. Middle East Vaxneuvance Market

    26.1. Middle East Vaxneuvance Market Overview

    26.2. Middle East Vaxneuvance Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

    26.3. Middle East Vaxneuvance Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

    26.4. Middle East Vaxneuvance Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

    27. Africa Vaxneuvance Market

    27.1. Africa Vaxneuvance Market Overview

    27.2. Africa Vaxneuvance Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

    27.3. Africa Vaxneuvance Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

    27.4. Africa Vaxneuvance Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

    28. Vaxneuvance Market Competitive Landscape And Company Profiles

    28.1. Vaxneuvance Market Competitive Landscape

    28.2. Vaxneuvance Market Company Profiles

    28.2.1. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis

    29. Global Vaxneuvance Market Pipeline Analysis

    29.1. High Level Clinic Trail Information

    30. Global Vaxneuvance Market Competitive Benchmarking And Dashboard

    31. Key Mergers And Acquisitions In The Vaxneuvance Market

    32. Recent Developments In The Vaxneuvance Market

    33. Vaxneuvance Market High Potential Countries, Segments and Strategies

    33.1 Vaxneuvance Market In 2029 - Countries Offering Most New Opportunities

    33.2 Vaxneuvance Market In 2029 - Segments Offering Most New Opportunities

    33.3 Vaxneuvance Market In 2029 - Growth Strategies

    33.3.1 Market Trend Based Strategies

    33.3.2 Competitor Strategies

    34. Appendix

    34.1. Abbreviations

    34.2. Currencies

    34.3. Historic And Forecast Inflation Rates

    34.4. Research Inquiries

    34.5. The Business Research Company

    34.6. Copyright And Disclaimer

List Of Tables

    Table 1: Global Historic Market Growth, 2019-2024, $ Million
  • Table 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Million
  • Table 3: Global Vaxneuvance Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Table 4: Global Vaxneuvance Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Table 5: Global Vaxneuvance Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Table 6: Global Vaxneuvance Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Table 7: Global Vaxneuvance Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Table 8: Asia-Pacific, Vaxneuvance Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Table 9: Asia-Pacific, Vaxneuvance Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Table 10: Asia-Pacific, Vaxneuvance Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Table 11: China, Vaxneuvance Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Table 12: China, Vaxneuvance Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Table 13: China, Vaxneuvance Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Table 14: India, Vaxneuvance Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Table 15: India, Vaxneuvance Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Table 16: India, Vaxneuvance Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Table 17: Japan, Vaxneuvance Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Table 18: Japan, Vaxneuvance Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Table 19: Japan, Vaxneuvance Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Table 20: Australia, Vaxneuvance Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Table 21: Australia, Vaxneuvance Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Table 22: Australia, Vaxneuvance Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Table 23: South Korea, Vaxneuvance Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Table 24: South Korea, Vaxneuvance Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Table 25: South Korea, Vaxneuvance Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Table 26: Western Europe, Vaxneuvance Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Table 27: Western Europe, Vaxneuvance Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Table 28: Western Europe, Vaxneuvance Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Table 29: UK, Vaxneuvance Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Table 30: UK, Vaxneuvance Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Table 31: UK, Vaxneuvance Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Table 32: Germany, Vaxneuvance Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Table 33: Germany, Vaxneuvance Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Table 34: Germany, Vaxneuvance Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Table 35: France, Vaxneuvance Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Table 36: France, Vaxneuvance Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Table 37: France, Vaxneuvance Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Table 38: Eastern Europe, Vaxneuvance Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Table 39: Eastern Europe, Vaxneuvance Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Table 40: Eastern Europe, Vaxneuvance Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Table 41: North America, Vaxneuvance Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Table 42: North America, Vaxneuvance Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Table 43: North America, Vaxneuvance Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Table 44: USA, Vaxneuvance Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Table 45: USA, Vaxneuvance Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Table 46: USA, Vaxneuvance Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Table 47: Canada, Vaxneuvance Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Table 48: Canada, Vaxneuvance Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Table 49: Canada, Vaxneuvance Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Table 50: South America, Vaxneuvance Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Table 51: South America, Vaxneuvance Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Table 52: South America, Vaxneuvance Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Table 53: Middle East, Vaxneuvance Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Table 54: Middle East, Vaxneuvance Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Table 55: Middle East, Vaxneuvance Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Table 56: Africa, Vaxneuvance Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Table 57: Africa, Vaxneuvance Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Table 58: Africa, Vaxneuvance Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Table 59: Merck & Co. Inc. Financial Performance

List Of Figures

    Figure 1: Global Historic Market Growth, 2019-2024, $ Million
  • Figure 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Million
  • Figure 3: Global Vaxneuvance Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Figure 4: Global Vaxneuvance Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Figure 5: Global Vaxneuvance Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Figure 6: Global Vaxneuvance Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Figure 7: Global Vaxneuvance Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Figure 8: Asia-Pacific, Vaxneuvance Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Figure 9: Asia-Pacific, Vaxneuvance Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Figure 10: Asia-Pacific, Vaxneuvance Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Figure 11: China, Vaxneuvance Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Figure 12: China, Vaxneuvance Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Figure 13: China, Vaxneuvance Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Figure 14: India, Vaxneuvance Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Figure 15: India, Vaxneuvance Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Figure 16: India, Vaxneuvance Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Figure 17: Japan, Vaxneuvance Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Figure 18: Japan, Vaxneuvance Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Figure 19: Japan, Vaxneuvance Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Figure 20: Australia, Vaxneuvance Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Figure 21: Australia, Vaxneuvance Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Figure 22: Australia, Vaxneuvance Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Figure 23: South Korea, Vaxneuvance Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Figure 24: South Korea, Vaxneuvance Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Figure 25: South Korea, Vaxneuvance Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Figure 26: Western Europe, Vaxneuvance Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Figure 27: Western Europe, Vaxneuvance Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Figure 28: Western Europe, Vaxneuvance Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Figure 29: UK, Vaxneuvance Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Figure 30: UK, Vaxneuvance Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Figure 31: UK, Vaxneuvance Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Figure 32: Germany, Vaxneuvance Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Figure 33: Germany, Vaxneuvance Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Figure 34: Germany, Vaxneuvance Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Figure 35: France, Vaxneuvance Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Figure 36: France, Vaxneuvance Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Figure 37: France, Vaxneuvance Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Figure 38: Eastern Europe, Vaxneuvance Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Figure 39: Eastern Europe, Vaxneuvance Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Figure 40: Eastern Europe, Vaxneuvance Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Figure 41: North America, Vaxneuvance Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Figure 42: North America, Vaxneuvance Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Figure 43: North America, Vaxneuvance Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Figure 44: USA, Vaxneuvance Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Figure 45: USA, Vaxneuvance Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Figure 46: USA, Vaxneuvance Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Figure 47: Canada, Vaxneuvance Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Figure 48: Canada, Vaxneuvance Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Figure 49: Canada, Vaxneuvance Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Figure 50: South America, Vaxneuvance Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Figure 51: South America, Vaxneuvance Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Figure 52: South America, Vaxneuvance Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Figure 53: Middle East, Vaxneuvance Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Figure 54: Middle East, Vaxneuvance Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Figure 55: Middle East, Vaxneuvance Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Figure 56: Africa, Vaxneuvance Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Figure 57: Africa, Vaxneuvance Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Figure 58: Africa, Vaxneuvance Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Figure 59: Merck & Co. Inc. Financial Performance

Global Protein Purification And Isolation Market 2022 – Market Opportunities And Strategies

Read More

What Is The Pharmaceutical Processing Seals Market Overview In 2022?

Read More

The Plasma Fractionation Market Share, Market Size, And Growth Rate 2022

Read More

The Biosimilar Therapeutic Peptides Market Share, Market Size, And Growth Rate 2022

Read More

The Business Research Company offers the plasma fractionation market research report 2022 with industry size, share, segments and market growth

Read More

The Business Research Company offers the hiv drugs market research report 2022 with industry size, share, segments and market growth

Read More

The Business Research Company offers the rituximab biosimilars market research report 2022 with industry size, share, segments and market growth

Read More

The Business Research Company offers the microbiome market research report 2022 with industry size, share, segments and market growth

Read More

Veterinary Vaccines Market 2024 – By Vaccine Type (Live Attenuated Vaccines, Inactivated Vaccines, Toxoid Vaccines, Recombinant Vaccines, Other Vaccine Types), By Disease Type (Anaplasmosis, Canine Parvovirus, Foot & Mouth Disease, Newcastle Disease, Distemper Disease, Influenza, Porcine Reproductive & Respiratory Syndrome (PRRS)), By Application (Livestock Vaccines, Companion Animal Vaccines), And By Region, Opportunities And Strategies – Global Forecast To 2033

View Report

H1N1 Vaccine Global Market Report 2025 – By Product Type( Inactivated Vaccine, Live Attenuated Vaccine ), By Route Of Administration( Intradermal Vaccination, Intramuscular Vaccination, Subcutaneous Vaccination ), By End Users( Hospitals, Clinics, Research and Diagnostic Laboratories, Other End Users) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Pediatric Vaccine Global Market Report 2025 – By Vaccine Type (Monovalent, Multivalent), By Technology (Live Attenuated, Inactivated, Toxoid, Conjugate, Other Technologies), By Application (Infectious Disease, Allergy, Cancer) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Companion Animal Veterinary Vaccines Global Market Report 2025 – By Product (Inactivated, Live Attenuated, Recombinant, Other Products), By Route Of Administration (Oral, Parenteral, Other Routes Of Administration), By Distribution Channel (Veterinary Hospitals, Veterinary Clinics, Pharmacies And Drug Stores, Other Distribution Channels) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Cancer Vaccines Global Market Report 2025 – By Type (Preventive Cancer Vaccines, Therapeutic Cancer Vaccines), By Technology (Dendritic Cells (DC) Cancer Vaccines, Recombinant Cancer Vaccines, Antigen/Adjuvant Cancer Vaccines, Whole Cell Cancer Vaccines, Viral Vector & DNA Cancer Vaccines), By Cancer Type (Prostate, Cervical, Colorectal, Throat, Other Cancer Types), By End-User (Cancer Treatment Centers, Research Institutes) – Market Size, Trends, And Global Forecast 2025-2034

View Report

DTP Vaccines Global Market Report 2025 – By Product type (DTaP, TD, Tdap), By Disease (Diphtheria, Pertussis, Tetanus), By End-User (Hospitals, Clinics, Vaccination Centers) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Pediatric Vaccine Market 2025 – By Vaccine Type (Monovalent Vaccines, Multivalent Vaccines), By Technology (Live Attenuated Vaccines, Inactivated Vaccines, Toxoid Vaccines, Conjugate Vaccines, Other Technologies), By Application (Infectious Disease, Allergy, Cancer, Pneumococcal Disease, Influenza, Measles, Mumps And Rubella, Other Applications), And By Region, Opportunities And Strategies – Global Forecast To 2034

View Report

Vaccines Market 2023 – By Type (Anti-Infective Vaccines, Anti-Cancer Vaccines, Other Type), By Technology (Conjugate Vaccines, Inactivated And Subunit Vaccines, Live Attenuated Vaccines, Recombinant Vaccines, Toxoid Vaccines, Other Technologies), By Route Of Administration (Intramuscular (IM), Subcutaneous (SC), Oral, Other Route of Administration), By Valance (Monovalent, Multivalent), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Institutional Sales), And By Region, Opportunities And Strategies – Global Forecast To 2032

View Report

Frequently Asked Questions

What is the definition of the Vaxneuvance market?

Vaxneuvance is a pneumococcal conjugate vaccine designed to protect against invasive diseases caused by specific strains of Streptococcus pneumoniae in adults and children. The vaccine works by stimulating the immune system to recognize and fight 15 serotypes of the bacteria, providing broad protection. For further insights on the Vaxneuvance market, request a sample here

How will the Vaxneuvance market drivers and restraints affect the market dynamics? What forces will shape the Vaxneuvance industry going forward?

The Vaxneuvance market major growth driver - Impact Of High Pneumonia Prevalence On Vaccine Demand. For further insights on the Vaxneuvance market, request a sample here

What is the forecast market size or the forecast market value of the Vaxneuvance market?

The Vaxneuvance market size has grown strongly in recent years. The vaxneuvance market size has XX (HCAGR) in recent years. It will grow from $XX million in 2024 to $XX million in 2025 at a compound annual growth rate (CAGR) of XX%. The growth in the historic period can be attributed to rise in incidence of pneumococcal diseases, rise in aging population, rise in supportive regulatory approvals, rise in government funding for vaccination, and increase in travel and globalization. The vaxneuvance market size is expected to see XX (FCAGR) in the next few years. It will grow to $XX million in 2029 at a compound annual growth rate (CAGR) of XX%. The growth in the forecast period can be attributed to rising chronic conditions, rising antimicrobial resistance, rising respiratory infections in children, increasing cases of immunocompromised populations, and rising healthcare investments. Major trends in the forecast period include development of needle-free vaccine delivery systems, advancements in cold-chain technologies, integration of AI-powered supply chain optimization, integration with digital health records for tracking immunizations, and innovations in adjuvant systems to boost immune response. For further insights on the Vaxneuvance market, request a sample here

How is the Vaxneuvance market segmented?

The vaxneuvance market covered in this report is segmented –
1) By Indication: Pneumonia; Meningitis; Sepsis; Bacteremia; Otitis Media
2) By Distribution Channel: Pharmacies; Hospitals
3) By End User: Adults; Children; Geriatric Population For further insights on the Vaxneuvance market, request a sample here

Which region has the largest share of the Vaxneuvance market? What are the other regions covered in the report?

North America was the largest region in the vaxneuvance market in 2024. The regions covered in the vaxneuvance market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. For further insights on the Vaxneuvance market, request a sample here.

Who are the major players in the Vaxneuvance market?

Major companies operating in the vaxneuvance market are Merck & Co. Inc. . For further insights on the Vaxneuvance market, request a sample here.

What are the key trends in the Vaxneuvance market?

Major trends in the Vaxneuvance market include Expanding Indications To Enhance Vaccine Accessibility And Impact. For further insights on the Vaxneuvance market, request a sample here.

What are the major opportunities in the Vaxneuvance market? What are the strategies for the Vaxneuvance market?

For detailed insights on the major opportunities and strategies in the Vaxneuvance market, request a sample here.

How does the Vaxneuvance market relate to the overall economy and other similar markets?

For detailed insights on Vaxneuvance's relation to the overall economy and other similar markets, request a sample here.

What are the latest mergers and acquisitions in the Vaxneuvance industry?

For detailed insights on the mergers and acquisitions in the Vaxneuvance industry, request a sample here.

What are the key dynamics influencing the Vaxneuvance market growth? SWOT analysis of the Vaxneuvance market.

For detailed insights on the key dynamics influencing the Vaxneuvance market growth and SWOT analysis of the Vaxneuvance industry, request a sample here.